Program
Imlunestrant
Also written as “LY3484356”, “Imlunestrant (Test)” and “Imlunestrant (Reference)”.
Its studies are mostly in Breast Neoplasms · Hepatic Insufficiency, led by Eli Lilly.
Furthest: phase 3, since Jul 22, 202112 company-led studies, 6 open or runningNext primary completion: Aug 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 126 open or running | phase 3since Jul 22, 2021 | Nov 18, 2019 | Aug 2027phase 1 · NCT07918859 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 18, 2019First study: phase 1 study in Breast NeoplasmsFirst studyNCT04188548 · 379 enrolled · United States, Australia, Belgium and more
- Nov 30, 2020Phase 1 study in Breast NeoplasmsNCT04647487 · 87 enrolled · United States, Belgium, France and more
- Apr 9, 2021Phase 1 study in HealthyNCT04840888 · 82 enrolled · United States
- Jul 22, 2021Phase 3 study in Breast NeoplasmsNCT04975308 · 874 enrolled · United States, Argentina, Australia and more
- Aug 2, 2021Phase 1 study in HealthyNCT04991766 · 16 enrolled · United States
- Jun 27, 20222 phase 1 studiesNCT05440344, NCT05444556
- Aug 19, 20222 phase 1 studiesNCT05509816, NCT05509790
- Aug 23, 2022Phase 3 study in Breast NeoplasmsNCT05514054 · 8,000 enrolled · United States, Argentina, Australia and more
- Dec 11, 2025Phase 2 study in Breast NeoplasmsNCT07287098 · 600 planned · United States, Belgium, France and more
- Nov 2, 2026Phase 1 study in HealthyNCT07918859 · 343 planned · United States
Ahead
- Aug 2027Primary completion: phase 1 study in HealthyNCT07918859
- Oct 2027Primary completion: phase 3 study in Breast NeoplasmsNCT05514054
- Jan 2029Primary completion: phase 2 study in Breast NeoplasmsNCT07287098
TargetBeta
ESR1 →read by rule
“An orally available selective estrogen receptor degrader (SERD), ”NCIt, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Fulvestrantrule | AstraZeneca | phase 4 | 30 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07918859Healthy · United States | 1 | Not yet recruiting | Aug 2027 | 343 |
| NCT07287098Breast Neoplasms · United States, Belgium, France and more | 2 | Recruiting | Jan 2029 | 600 |
| NCT05514054Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 2027 | 8,000 |
| NCT05509816Healthy · United States | 1 | Completed | Nov 30, 2022 | 20 |
| NCT05509790Breast Neoplasms · China | 1 | Active, not recruiting | Feb 18, 2024 | 17 |
| NCT05444556Healthy · United States | 1 | Completed | Nov 2, 2022 | 113 |
| NCT05440344Hepatic Insufficiency · United States | 1 | Completed | Feb 28, 2024 | 27 |
| NCT04991766Healthy · United States | 1 | Completed | Apr 2, 2022 | 16 |
| NCT04975308Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jun 24, 2024 | 874 |
| NCT04840888Healthy · United States | 1 | Completed | Apr 12, 2022 | 82 |
| NCT04647487Breast Neoplasms · United States, Belgium, France and more | 1 | Completed | Nov 11, 2022 | 87 |
| NCT04188548Breast Neoplasms · United States, Australia, Belgium and more | 1 | Active, not recruiting | Jun 29, 2020 | 379 |
How it is read
Names in the registry
- “Imlunestrant”, 6 entries
- “LY3484356”, 5 entries
- “Imlunestrant (Test)”, 1 entry
- “Imlunestrant (Reference)”, 1 entry
- “[¹⁴C]-LY3484356”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 6 studies
- Hepatic Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.